Orasure Technologies Inc. logo

Orasure Technologies Inc. (EP3)

Market Closed
16 Jul, 12:18
XSTU XSTU
3. 68
-0.02
-0.5405%
- Market Cap
7.33 P/E Ratio
- Div Yield
847 Volume
-0.13 Eps
3.7
Previous Close
Add Transaction
Day Range
3.68 3.72
Year Range
1.82 3.94
Want to track EP3 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

EP3 closed Thursday lower at €3.68, a decrease of -0.5405% from Wednesday's close, completing a monthly decrease of -5.1546% or -€0.2. Over the past 12 months, EP3 stock gained 80.3922%.
EP3 is not paying dividends to its shareholders.
The last earnings report, released on May 06, 2026, exceeded the consensus estimates by 0.16%. On average, the company has surpassed earnings expectations by 0.1533%, based on the last three reports.
Orasure Technologies Inc. has completed 1 stock splits, with the recent split occurring on Apr 08, 1987.
The company's stock is traded on 5 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).

EP3 Chart

OraSure Technologies, Inc. (OSUR) Q1 2026 Earnings Call Transcript

OraSure Technologies, Inc. (OSUR) Q1 2026 Earnings Call Transcript

OraSure Technologies, Inc. (OSUR) Q1 2026 Earnings Call Transcript

Seekingalpha | 2 months ago
OraSure Files for FDA Review of Molecular Self-Test & Colli-Pee Device

OraSure Files for FDA Review of Molecular Self-Test & Colli-Pee Device

OSUR files FDA applications seeking approval for two at-home STI tests, advancing decentralized diagnostics; shares gain 3.8% as it targets long-term growth.

Zacks | 6 months ago
OraSure Technologies, Inc. (OSUR) Q3 2025 Earnings Call Transcript

OraSure Technologies, Inc. (OSUR) Q3 2025 Earnings Call Transcript

OraSure Technologies, Inc. ( OSUR ) Q3 2025 Earnings Call November 5, 2025 5:00 PM EST Company Participants Jason Plagman - Vice President of Investor Relations Carrie Eglinton Manner - President, CEO & Director Kenneth McGrath - Chief Financial Officer Conference Call Participants Steven Etoch - Stephens Inc., Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the OraSure Technologies, Inc. 2025 Third Quarter Earnings Conference Call.

Seekingalpha | 8 months ago

Orasure Technologies Inc. (EP3) FAQ

What is the stock price today?

The current price is €3.68.

On which exchange is it traded?

Orasure Technologies Inc. is listed on XSTU.

What is its stock symbol?

The ticker symbol is EP3.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Orasure Technologies Inc. ever had a stock split?

Orasure Technologies Inc. had 1 splits and the recent split was on Apr 08, 1987.

Orasure Technologies Inc. Profile

Electronic Equipment, Instruments & Components Industry
Information Technology Sector
Carrie Eglinton Manner CEO
XSTU Exchange
68554V108 CUSIP
US Country
501 Employees
8 Jan 1998 Last Dividend
8 Apr 1987 Last Split
12 Nov 1986 IPO Date

Overview

OraSure Technologies, Inc., founded in 2000 and headquartered in Bethlehem, Pennsylvania, operates globally offering a wide range of diagnostic solutions, specimen collection devices, and microbiome laboratory services. The company plays a pivotal role in public health by providing innovative products for the diagnosis of critical conditions such as HIV, hepatitis C (HCV), Ebola, and COVID-19 along with substance abuse testing. OraSure’s commitment to improving healthcare accessibility is evident in its development of both point-of-care and home diagnostic tests, catering to a diverse clientele including clinical laboratories, hospitals, public health organizations, and more. Their offerings have found international application in various sectors including healthcare, government, and environmental markets, making it a significant player in the diagnostics field.

Products and Services

The comprehensive range of products and services from OraSure Technologies, Inc. underscores its mission to deliver reliable and convenient diagnostic solutions:

  • COVID-19 Rapid Tests: The InteliSwab COVID-19 rapid tests including versions for professional and Rx use, offer quick and easy solutions for detecting the COVID-19 virus, simplifying testing across settings.
  • HIV Testing Solutions: Products such as OraQuick Rapid HIV test, the In-Home HIV test, and the HIV self-test facilitate prompt, private, and accurate HIV testing.
  • HCV Rapid Antibody Test: The OraQuick HCV test provides rapid detection of hepatitis C antibodies, making HCV screening more accessible.
  • Ebola Rapid Antigen Test: This test offers critical rapid diagnostic capabilities for Ebola virus detection, particularly significant in epidemic responses.
  • Oral Fluid Collection Device: Used for screening and confirmatory tests for HIV-1 antibodies, enhancing the ease and safety of sample collection.
  • Intercept Drug Testing Systems: These systems cater to the need for reliable drug abuse testing in various settings.
  • Q.E.D. Saliva Alcohol Test: Offers a simple and effective means for detecting alcohol levels, ensuring workplace and road safety.
  • Genomic Products: Including Oragene and ORAcollect brands, these products streamline the collection of genetic material from saliva for diverse genetic analyses.
  • Urine Sample Collection: The Colli-Pee devices facilitate the volumetric collection of urine samples, optimizing specimen collection for diagnostics.
  • Microbiome Laboratory Testing and Services: Through platforms like OMNIgene GUT, the company offers comprehensive solutions for gut microbiome profiling, supporting a burgeoning field in human health research.
  • Immunoassay Tests and Reagents: A variety of diagnostic products fall under this category, providing essential tools for the detection of various pathogens and conditions.

These offerings underline OraSure Technologies, Inc.'s commitment to advancing health diagnostics, ensuring that critical health information is accessible, reliable, and timely.

Contact Information

Address: 220 East First Street
Phone: 610 882 1820